18 completed, 3 unknown, 1 withdrawn. 12 Phase 4, 6 Phase 3, 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Completed 9, Unknown 2, Withdrawn 1 |
| Phase 3 | 6 | Completed 5, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow tafluprost: new trials by email Literature Review of tafluprost trials Research Report on tafluprost
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting Tafluprost, timolol maleate - Ocular Surface Disease, Primary Open Angle Glaucoma | Completed | Santen Pharmaceutical (Taiwan) Co., LTD | 50 | 2021-09-01 | 2022-10-31 | |
| 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration. tafluprost/timolol - Glaucoma, Open-Angle, Ocular Hypertension | Phase 4 | Unknown | Fondazione G.B. Bietti, IRCCS | 43 | 2020-06-04 | 2022-03-29 |
| Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients Latanoprost 0.005% Ophthalmic Solution, Travoprost 0.004% ophthalmic solution, Tafluprost Ophthalmic 0.0015% Ophthalmic Solution - Primary Open Angle Glaucoma | Completed | Kasr El Aini Hospital | 60 | 2019-06-01 | 2020-07-08 | |
| A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Santen Pharmaceutical Co., Ltd. | 219 | 2019-01-20 | 2023-07-14 |
| Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution) Latanoprost, tafluprost - Glaucoma, Primary Open Angle | Not applicable | Completed | Santen Pharmaceutical (Taiwan) Co., LTD | 1 | 2018-04-02 | 2021-02-04 |
| Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing Tafluprost/timolol fixed combination - Glaucoma, Open-Angle | Phase 4 | Completed | Aristotle University Of Thessaloniki | 42 | 2017-01-01 | 2020-12-17 |
| A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness Tafluprost 15µg/ml - Glaucoma, Open-Angle, Ocular Hypertension | Phase 4 | Completed | Ordination Dr. Hommer | 30 | 2016-05-10 | 2017-08-23 |
| Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Preserved Bimatoprost 0.01%, Tafluprost Unit Dose Preservative Free 15microgram/ml - Ocular Hypertension, Glaucoma | Phase 4 | Unknown | Universitaire Ziekenhuizen KU Leuven | 67 | 2015-09-01 | 2016-05-12 |
| 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy tafluprost, tafluprost and dorzolamide/timolol - Glaucoma, Ocular Surface Disease | Phase 4 | Completed | Aristotle University Of Thessaloniki | 43 | 2015-03-01 | 2020-12-17 |
| The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Prostaglandin Analog, Timolol - Thyroid Eye Disease, Ocular Hypertension | Phase 4 | Withdrawn | Stanford University | 2014-06-01 | 2018-05-15 | |
| An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Dr. Anton Hommer | 16 | 2013-10-01 | 2015-04-23 |
| Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Benzalkonium chloride (BAK), 0.0015% tafluprost - Primary Open-angle Glaucoma | Phase 4 | Completed | Gangnam Severance Hospital | 20 | 2013-03-01 | 2017-04-07 |
| A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost - Glaucoma and Ocular Hypertension | Phase 1 / Phase 2 | Completed | Santen Inc. | 60 | 2012-07-01 | 2018-04-18 |
| Switching From Preserved to Preserved-free Treatments for Glaucoma. Tafluprost, Latanoprost - Glaucoma | Phase 3 | Unknown | Paolo Fogagnolo | 40 | 2012-05-01 | 2014-05-16 |
| Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Goldmann and Perkins applanation tonometry, TAFLUPROST 0.0015% EYEDROPS, LATANOPROST 0.005% EYEDROPS - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 40 | 2011-03-01 | 2013-05-07 |
| Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations Timolol and Tafluprost, Fixed Dose Combination of tafluprost and timolol - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Santen Oy | 401 | 2011-03-01 | 2012-06-08 |
| Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon Research | 47 | 2011-03-01 | 2014-05-20 |
| Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies Timolol/ FDC/ Placebo/ Tafluprost - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Santen Oy | 600 | 2011-02-01 | 2013-03-13 |
| The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma Tafluprost 0.0015% - Ocular Hypertension, Open-Angle Glaucoma | Phase 4 | Completed | FinnMedi Oy | 30 | 2010-08-01 | 2014-10-28 |
| Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops tafluprost - Ocular Hypertension, Open-Angle Glaucoma | Phase 3 | Completed | Santen Oy | 185 | 2010-04-01 | 2013-05-31 |
Showing 20 of 22. Sign in to see all of them.
Glaucoma, Open-Angle (16) · Ocular Hypertension (14) · Glaucoma (9) · Graves Disease (1) · Graves Ophthalmopathy (1)
Santen Oy (4) · Alcon Research (2) · Aristotle University Of Thessaloniki (2) · Santen Pharmaceutical (Taiwan) Co., LTD (2) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Dr. Anton Hommer (1) · FinnMedi Oy (1) · Fondazione G.B. Bietti, IRCCS (1) · Gangnam Severance Hospital (1) · Kasr El Aini Hospital (1) · Ordination Dr. Hommer (1) · Paolo Fogagnolo (1) · Santen Inc. (1) · Santen Pharmaceutical Co., Ltd. (1) · Stanford University (1)
Italy (4) · Austria (3) · Finland (3) · Greece (2) · Taiwan (2) · United States (2) · Belgium (1) · China (1) · Egypt (1) · Hungary (1) · Switzerland (1) · United Kingdom (1)
Auli Ropo, M.D. (2) · Luca Rossetti, MD (2) · Luciano Quaranta, MD (2) · Anastasios G Konstas, MD, PhD (1) · Andrea L. Kossler, M.D. (1) · Clemens Vass, M.D. (1) · Eva Ruzickova, M.D. (1) · Evgeniy Egorov, Professor (1) · Francesco Oddone, MD (1) · Gong Je Seong (1) · Guna Laganovska, M.D. (1) · Hannu Uusitalo, M.D., Prof. (1) · Hannu Uusitalo, MD, PhD (1) · Hannu Uusitalo, Professor (1)
PMID 20553122, PMID 23681371, PMID 25447269, PMID 25893514, PMID 27913991, PMID 28454526, PMID 30328725, PMID 33818170